Logo image of MGRX

MANGOCEUTICALS INC (MGRX) Stock Fundamental Analysis

NASDAQ:MGRX - Nasdaq - US56270V2051 - Common Stock - Currency: USD

2.04  -0.2 (-8.93%)

After market: 2 -0.04 (-1.96%)

Fundamental Rating

1

MGRX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 40 industry peers in the Consumer Staples Distribution & Retail industry. Both the profitability and financial health of MGRX have multiple concerns. MGRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MGRX has reported negative net income.
MGRX had a negative operating cash flow in the past year.
MGRX Yearly Net Income VS EBIT VS OCF VS FCFMGRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -2M -4M -6M -8M

1.2 Ratios

Looking at the Return On Assets, with a value of -63.05%, MGRX is doing worse than 97.50% of the companies in the same industry.
Looking at the Return On Equity, with a value of -69.65%, MGRX is doing worse than 85.00% of the companies in the same industry.
Industry RankSector Rank
ROA -63.05%
ROE -69.65%
ROIC N/A
ROA(3y)-384.72%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MGRX Yearly ROA, ROE, ROICMGRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 -200 -400 -600 -800 -1K

1.3 Margins

With an excellent Gross Margin value of 58.60%, MGRX belongs to the best of the industry, outperforming 95.00% of the companies in the same industry.
MGRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MGRX Yearly Profit, Operating, Gross MarginsMGRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 0 -5K -10K -15K -20K

More info and screens

2

2. Health

2.1 Basic Checks

MGRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MGRX has more shares outstanding
There is no outstanding debt for MGRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MGRX Yearly Shares OutstandingMGRX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 500K 1M
MGRX Yearly Total Debt VS Total AssetsMGRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 200K 400K 600K 800K 1M

2.2 Solvency

An Altman-Z score of 2.26 indicates that MGRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
MGRX has a worse Altman-Z score (2.26) than 67.50% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that MGRX is not too dependend on debt financing.
MGRX has a Debt to Equity ratio of 0.01. This is amongst the best in the industry. MGRX outperforms 82.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 2.26
ROIC/WACCN/A
WACC9.02%
MGRX Yearly LT Debt VS Equity VS FCFMGRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 -2M -4M -6M

2.3 Liquidity

A Current Ratio of 0.07 indicates that MGRX may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.07, MGRX is doing worse than 97.50% of the companies in the same industry.
A Quick Ratio of 0.07 indicates that MGRX may have some problems paying its short term obligations.
MGRX has a worse Quick ratio (0.07) than 97.50% of its industry peers.
Industry RankSector Rank
Current Ratio 0.07
Quick Ratio 0.07
MGRX Yearly Current Assets VS Current LiabilitesMGRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 200K 400K 600K 800K

More info and screens

1

3. Growth

3.1 Past

MGRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1021.58%.
The Revenue has grown by 52.24% in the past year. This is a very strong growth!
EPS 1Y (TTM)-1021.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-778.5%
Revenue 1Y (TTM)52.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-45.6%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MGRX Yearly Revenue VS EstimatesMGRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 200K 400K 600K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MGRX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MGRX Price Earnings VS Forward Price EarningsMGRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGRX Per share dataMGRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

MGRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MANGOCEUTICALS INC

NASDAQ:MGRX (4/23/2025, 8:21:59 PM)

After market: 2 -0.04 (-1.96%)

2.04

-0.2 (-8.93%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners3.01%
Inst Owner Change0%
Ins Owners22.1%
Ins Owner Change18.18%
Market Cap12.75M
AnalystsN/A
Price TargetN/A
Short Float %2.01%
Short Ratio0.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.89
P/FCF N/A
P/OCF N/A
P/B 0.95
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.88
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.87
OCFYN/A
SpS0.12
BVpS2.14
TBVpS-0.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.05%
ROE -69.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.6%
FCFM N/A
ROA(3y)-384.72%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.07
Quick Ratio 0.07
Altman-Z 2.26
F-Score3
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1021.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-778.5%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)52.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-45.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-403.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-419.67%
OCF growth 3YN/A
OCF growth 5YN/A